FDA Speeds Testing of Two Therapies for Ovarian Cancer Targeting HER2

FDA Speeds Testing of Two Therapies for Ovarian Cancer Targeting HER2
Zymeworks announced that the U.S. Food and Drug Administration (FDA) has granted its lead investigational products, ZW25 and ZW33, orphan drug designation as potential treatments for ovarian cancer (OC). The company’s lead therapeutic program, ZW25, is an investigational, bi-specific antibody, developed using the company’s Azymetric platform, that targets two different epitopes of the human epidermal growth factor receptor

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *